Vanguard Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.8M Buy
3,088,536
+115,607
+4% +$420K ﹤0.01% 2765
2026
Q2
$11.6M Buy
2,972,929
+479,192
+19% +$1.78M ﹤0.01% 2735
2026
Q1
$9.6M Buy
+2,493,737
New +$9.9M ﹤0.01% 2756

Other funds holding SABS

Vanguard Capital Management's SABS Position: Q3 2026 in Review

Vanguard Capital Management increased its SAB Biotherapeutics (SABS) stake by 3.9% in Q3 2026, buying an estimated $420K and bringing the position to 3,088,536 shares worth $9.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

Vanguard Capital Management first reported a position in SABS in Q1 2026 and has held it in 3 quarters since. The position peaked at $11.6M in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Vanguard Capital Management held 3,088,536 shares of SAB Biotherapeutics worth $9.8M as of Q3 2026.
  • Vanguard Capital Management bought 115,607 SAB Biotherapeutics shares in Q3 2026, an estimated $420K.
  • SAB Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2765 holding.
  • Vanguard Capital Management first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's SAB Biotherapeutics position peaked at $11.6M in Q2 2026.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.